PharmaCyte Biotech (PMCB) Assets Average (2011 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Assets Average of $51.3 million for Q2 2026, up 3.67% year-over-year from $49.5 million in Q2 2025, and down 8.25% quarter-over-quarter from $55.9 million in Q1 2026.
PharmaCyte Biotech (PMCB) Assets Average (2011 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Assets Average for 16 consecutive years, with $51.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Assets Average rose 3.67% year-over-year to $51.3 million; the TTM figure through Apr 2026 stood at $51.3 million (up 3.67% YoY), while the FY2026 annual figure was $51.0 million, down 11.43% from the prior year.
- Assets Average retreated to $51.3 million in Q2 2026 per PMCB's latest filing, from $55.9 million in the prior quarter.
- Across five years, Assets Average topped out at $92.1 million in Q1 2022 and bottomed at $49.5 million in Q1 2025.
- Historically, Assets Average has averaged $69.1 million across 5 years, with a median of $70.4 million in 2024.
- Annual changes were most pronounced in 2022 — Assets Average soared 1167.73% — and 2025, when it plunged 34.15%.
- PharmaCyte Biotech's Assets Average stood at $84.9 million in 2022, then slipped by 6.47% to $79.4 million in 2023, then dropped by 21.08% to $62.6 million in 2024, then dropped by 19.32% to $50.5 million in 2025, then increased by 1.52% to $51.3 million in 2026.
- Business Quant data shows PMCB's Assets Average at $51.3 million in Q2 2026, $55.9 million in Q1 2026, and $50.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.96 Bn | 132.11 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.20 Bn | 55.06 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.19 Bn | 37.09 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.43 Bn | 28.12 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 19.82 Bn |
| 10 | PharmaCyte Biotech | 4.44 Mn | 4.44 Mn | - | 51.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 51.31 Mn |
| Jan 31, 2026 | 55.93 Mn |
| Oct 31, 2025 | 50.54 Mn |
| Jul 31, 2025 | 50.14 Mn |
| Apr 30, 2025 | 49.50 Mn |
| Jan 31, 2025 | 49.46 Mn |
| Oct 31, 2024 | 62.65 Mn |
| Jul 31, 2024 | 65.05 Mn |
| Apr 30, 2024 | 65.63 Mn |
| Jan 31, 2024 | 75.12 Mn |
| Oct 31, 2023 | 79.38 Mn |
| Jul 31, 2023 | 76.58 Mn |
| Apr 30, 2023 | 75.61 Mn |
| Jan 31, 2023 | 80.15 Mn |
| Oct 31, 2022 | 84.87 Mn |
| Jul 31, 2022 | 89.00 Mn |
| Apr 30, 2022 | 91.28 Mn |
| Jan 31, 2022 | 92.13 Mn |
| Oct 31, 2021 | 49.47 Mn |
| Jul 31, 2021 | 7.02 Mn |